Department of Pulmonary Diseases, VU University Medical Center, Amsterdam, The Netherlands.
J Thorac Oncol. 2010 Sep;5(9):1477-80. doi: 10.1097/JTO.0b013e3181e981d9.
Currently, the inhibitor of the epidermal growth factor receptor tyrosine kinase erlotinib is widely used for the treatment of non-small cell lung cancer. Patients with a mutation or deletion in the epidermal growth factor receptor gene will benefit most and are likely to receive the drug for long periods and willing to accept side effects if responding.
Twenty-two cases with prolonged administration of erlotinib (at least 6 months) and side effects are reported. Three cases with specific side effects are described in detail.
In addition to the well-known side effects such as folliculitis and diarrhea, patients reported paronychia, fatigue, and hair changes.
After prolonged administration of erlotinib in most patients, the initial side effects persist while other inconvenient ones may develop. This may lead to dose reductions or even cessation of treatment.
目前，表皮生长因子受体酪氨酸激酶抑制剂厄洛替尼被广泛用于治疗非小细胞肺癌。表皮生长因子受体基因突变或缺失的患者将从中获益最大，并且可能需要长期服用该药，并且在有疗效的情况下愿意接受副作用。
报告了 22 例接受厄洛替尼长期（至少 6 个月）治疗且出现不良反应的病例。详细描述了 3 例具有特定副作用的病例。
除了众所周知的副作用，如毛囊炎和腹泻外，患者还报告了甲沟炎、疲劳和头发变化。
在大多数患者接受厄洛替尼长期治疗后，最初的副作用持续存在，而其他不便的副作用可能会出现。这可能导致剂量减少甚至停止治疗。
